Oragenics (OGEN) Long-Term Debt Issuances (2010 - 2025)

Oragenics' (OGEN) quarterly Long-Term Debt Issuances came in at -$167488.0 in Q4 2025, down 142.42% on a QoQ basis from $394836.0 in Q3 2025.

Oragenics (OGEN) Long-Term Debt Issuances (2010 - 2025) Analysis & Trends

Oragenics (OGEN) has 4 years of Long-Term Debt Issuances data on file, last reported at -$167488.0 in Q4 2025.

Quarterly Long-Term Debt Issuances changed N/A year-over-year to -$167488.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $2.5 million (changed N/A YoY) and the FY2025 annual result came in at $2.5 million, changed N/A from the prior year.
Long-Term Debt Issuances fell to -$167488.0 in Q4 2025, from $394836.0 in the prior quarter.
In the past five years, Long-Term Debt Issuances ranged from a high of $2.2 million in Q1 2025 to a low of -$167488.0 in Q4 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Issuances (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	-
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	-
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	-
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	-
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	Oragenics	2.31 Mn	2.31 Mn	-	-

Download Data